Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP761 Phase I Study in Healthy Volunteers
NCT06637865Phase 1Completed
- Sponsor
- Immutep Limited
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IMP761 in autoimmune disease (6 arms), sponsored by Immutep Limited. Primary endpoints: Occurrence of clinically relevant abnormalities in vital signs up to 143 days, Frequency of adverse events up to 103 days and 4 more. Started Jul 2024; status: completed.
02
Drugs
IMP761
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT06637865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637865.